Key Clinical Trial Terms
Clinical Trial Phase
The stages of testing a drug: Phase 1 (Safety and dosing), Phase 2 (Preliminary efficacy and dosing in patients), Phase 3 (Comparison to standard treatment in large groups), and Phase 4 (Long-term monitoring after approval).
NCT Number
A unique identification number assigned to each clinical trial (e.g., NCT01234567). It serves as the "ID card" for the study in global databases.
Recruiting
The status indicating that a clinical trial is currently open and looking for new participants to join.
Protocol
The detailed plan that describes how a clinical trial will be conducted, including treatment dosing, visit schedule, tests, and procedures. When doctors say "the protocol," they are referring to this plan.
Principal Investigator (PI)
The lead doctor responsible for conducting and overseeing the clinical trial at a specific medical site.
Sponsor
The organization (pharmaceutical company, hospital, or agency) that initiates, manages, and finances the clinical trial.
Standard of Care
The treatment currently accepted by medical experts as the most effective for a specific disease.
Inclusion Criteria
The specific requirements (age, disease type, genetic mutations) that a patient must meet to be eligible for the trial.
Exclusion Criteria
Specific factors or medical conditions that prevent a patient from participating in a trial.
Eligibility
The overall status of whether a patient fits the study protocol based on the inclusion and exclusion criteria.
Informed Consent
The process of providing patients with all relevant information about a trial (risks, benefits, rights) before they agree to participate.
Screening
The period of tests (scans, bloodwork) conducted before a patient officially joins a trial to confirm they meet all eligibility requirements.
Randomized Trial
A study design where participants are assigned to different treatment groups by chance, rather than by choice.
Control Group
The group in a trial that receives the standard treatment or a placebo, used as a baseline to measure the effectiveness of the new drug.
Placebo
An inactive substance used for comparison. In modern cancer trials, a placebo is almost always added on top of the standard treatment, not given as a replacement. This means no patient goes untreated.
Double-Blind Study
A trial where neither the participants nor the doctors know who is receiving the experimental treatment and who is in the control group. This design reduces bias in the results.
Open-Label Study
A trial where both patients and doctors know which treatment is being given. There is no blinding. Common in early-phase trials and single-arm studies.
Biomarker
A measurable characteristic in the body (like a genetic mutation, protein level, or blood marker) used to determine if a patient is eligible for a specific trial. For example, an EGFR mutation or PD-L1 expression level can determine which trials are relevant for a patient.
Performance Status (ECOG)
A score (0 to 5) measuring how well a patient can carry out daily activities. Most trials require an ECOG score of 0 or 1, meaning the patient is fully active or restricted in strenuous activity but can still walk and carry out light work. This is one of the most common reasons patients are found ineligible for trials.
Adverse Event (AE)
Any unwanted medical occurrence during participation in a clinical trial, whether or not it is caused by the treatment. All adverse events are documented and monitored closely.
Expanded Access / Compassionate Use
A pathway for patients with serious conditions to access experimental drugs outside of a formal clinical trial when no other treatment options exist.
Basket Trial
A trial that tests a drug on patients with different types of cancer that share a common genetic mutation or biomarker. Instead of focusing on where the cancer is located, it focuses on what drives it genetically.
Natural History Study
An observational study that tracks how a disease progresses over time in patients, without testing any treatment. These studies are especially important in rare diseases, where being enrolled can put patients first in line for future treatment trials.
This article was written by a patient advocate based on personal experience, not by a medical professional. It is not medical advice. Consult your doctor before making any medical decisions.